Weekly injection (phase 2)
Trial- Dose
- 2.5, 5, 10 or 15 mg
- How often
- Once weekly
- How long
- 13 weeks
Stepped up every 3 weeks to the final dose. 15 mg gave 14.7% mean loss vs 1.7% on placebo, if all stayed on treatment, with no plateau yet.
Human studiesGLP-1 and GIP receptor dual agonist
VK2735
VK-2735 (Viking Therapeutics code; no generic name yet)
- Common dose
- 2.5–17.5 mg weekly (trials)
- Cycle
- Continuous
- Form
- In trials only
An investigational weekly injection, also tested as a daily tablet, that activates the GLP-1 and GIP receptors, the same pair tirzepatide targets. It reduces appetite and food intake.
Evidence. Investigational (Viking Therapeutics). In the 13-week phase 2 VENTURE trial (176 adults), weekly injections lowered weight 9.1–14.7% vs 1.7% on placebo, if everyone had stayed on treatment; a daily tablet gave up to 12.2% vs 1.3% in 13 weeks (press release, August 2025). Two 78-week phase 3 trials (VANQUISH) began in June 2025, are fully enrolled and are due to finish in mid-2027.
What it’s used for
None of these uses is approved. Uses tested in people come first, then claims that rest on animal studies or user reports.
- Weight loss in obesity or overweight
- TrialPromising, not approved: in a 13-week phase 2 trial of 176 adults without diabetes, weekly injections cut weight 9.1–14.7% vs 1.7% on placebo, if all stayed on treatment.
- Weight loss with a daily tablet
- TrialUp to 12.2% vs 1.3% on placebo in 13 weeks in 280 adults, but 20% stopped for side effects vs 13% (press release, August 2025). Not approved.
- Keeping weight off with less frequent doses
- TrialAfter 21 weekly doses, every-other-week or monthly injections kept 82–97% of the loss over 12 weeks vs 61% on placebo (press release, September 2026).
- Weight loss with type 2 diabetes
- No studyUnproven: a 78-week phase 3 trial in about 1,000 adults with type 2 diabetes (VANQUISH 2) is under way and due to finish in mid-2027.
- Blood pressure
- TrialSystolic pressure fell 6.7–11.0 mmHg vs 4.2 on placebo over 13 weeks, a secondary measure in a short trial, not a confirmed benefit.
Trial: tested in people, with the result. No study: nothing published supports it.
Every compound’s uses, by body system: evidence map, and by condition: conditions A to Z.
Status
- Approval
- Not approved in the US or anywhere else. Viking Therapeutics began two phase 3 trials (VANQUISH) in June 2025; both are due to finish in mid-2027.
- US compounding
- Never nominated for FDA’s 503A or 503B bulk lists and not in any of FDA’s compounding categories (lists updated May 2026 and March 2025). It isn’t part of any approved drug, so it can’t legally be compounded.
- European Union
- No marketing authorization; it is still in clinical trials.
- United Kingdom
- No marketing authorization; it is still in clinical trials.
- Canada
- No marketing authorization; Health Canada’s Drug Product Database lists no VK2735 product.
- Australia
- No product registered, and VK2735 isn’t named in the Poisons Standard (October 2026).
- Sport (WADA 2026)
- Likely banned in sportNot named on WADA’s 2026 list, but its S0 rule bans drugs with no current human approval anywhere, at all times.
- In the news
- October 6, 2026: VK2735 maintenance study adds tablet arms in part 2. September 22, 2026: VK2735 kept most weight off with less frequent doses. Research digest
Category 2 is FDA’s list of bulk substances that may present significant safety risks in compounding. The 503A bulks list adds substances that pharmacies may compound with. Advisory committee votes are advice; FDA makes the final decision. Sport status follows the WADA Prohibited List in force since January 1, 2026; athletes should confirm with their anti-doping organization. Checked October 5, 2026. Status outside the US checked October 7, 2026 against EMA, MHRA, Health Canada and TGA records. By country: EU, UK, Canada, Australia. Status of every compound.
How it works
VK2735 is an experimental peptide that switches on two gut-hormone receptors, GLP-1 and GIP, the same pair tirzepatide targets. GLP-1 signals curb appetite and slow stomach emptying, and both hormones boost insulin release after meals. A side chain lets it last long enough for weekly injections, and a tablet form is also being tested. In trials it lowered weight within 13 weeks.
TrialMainly from studies in people.
Not known
Its structure and how strongly it acts on each receptor haven’t been fully published, and only 13 weeks of data are in a journal. Effects beyond 33 weeks, including on the heart, are unknown.
Protocol
Trial
Bays 2026
Weekly injection (phase 2, VENTURE): 2.5, 5, 10 or 15 mg for 13 weeks, stepped up every 3 weeks to the final dose (15 mg: 5, 7.5, 10, then 15 mg). Weight fell 9.1–14.7% vs 1.7% on placebo, if everyone had stayed on treatment.
Trial
Viking press release, Aug 2025
Daily tablet (phase 2): 15–120 mg once a day for 13 weeks, stepped up every 2 weeks. Weight fell up to 12.2% vs 1.3% on placebo, but 20% stopped for side effects vs 13%.
Trial
VANQUISH 1 and 2
Phase 3 (VANQUISH): 7.5, 12.5 or 17.5 mg once weekly for 78 weeks; due to finish in mid-2027.
- Frequency
- Once weekly (injection); once daily (tablet, phase 2)
- Route
- Subcutaneous injection (trials); daily tablet in a phase 2 trial
- Cycle
- Continuous in trials (13–33 weeks so far; phase 3 runs 78 weeks). A 2026 study tested every-other-week and monthly doses after 21 weekly ones.
Continuous, shown over 26 weeks
Common protocols
The ways VK2735 is most often run, each tagged with where it comes from.
Daily tablet (phase 2)
Trial- Dose
- 15–120 mg
- How often
- Once daily
- How long
- 13 weeks
Up to 12.2% loss vs 1.3% on placebo; nausea 58% vs 48%, and 20% stopped for side effects vs 13% (press release, August 2025).
Maintenance study
Trial- Dose
- 15–22.5 mg weekly, then 5–10 mg every other week or 10–22.5 mg monthly
- How often
- Weekly for 21 weeks, then every 2 or 4 weeks
- How long
- 33 weeks
16–19% loss at 21 weeks. Every-other-week doses kept 83–97% of it and monthly doses 82–90%, vs 61% after switching to placebo (press release, September 2026).
Phase 3 (VANQUISH)
Trial- Dose
- 7.5, 12.5 or 17.5 mg
- How often
- Once weekly
- How long
- 78 weeks
About 4,500 adults without diabetes and about 1,000 with type 2 diabetes; fully enrolled, due to finish in mid-2027.
VENTURE 15 mg arm (phase 2)
| Period | Dose |
|---|---|
| Weeks 1–3 | 5 mg |
| Weeks 4–6 | 7.5 mg |
| Weeks 7–9 | 10 mg |
| Weeks 10–13 | 15 mg |
Taking it
Where it goes
Injected under the skin once a week in trials; tablets were swallowed once a day. Published reports don’t name injection sites; weekly injections usually go in the belly, thigh or upper arm.
If you miss a dose
No label or published trial rule. Common practice with weekly injections is to take the next dose on schedule without doubling up. For comparison, the Zepbound (tirzepatide) label allows a missed dose within 4 days; after that, skip it.
What to expect
- Weeks 1–13
Nausea was most common early and during dose steps; after the first week, no more than 5% of people reported nausea in any given week.
Trial - Week 13
9.1–14.7% mean loss vs 1.7% on placebo, if all stayed on treatment; 88% on 15 mg lost at least 10%, vs 4% on placebo. No plateau yet.
Trial - Week 21
In a maintenance study, weekly doses of 15–22.5 mg gave 16–19% mean loss vs about 0% on placebo (press release, September 2026).
Trial - Week 33
17.5 mg weekly reached 21.7% loss vs a 0.3% gain on placebo; people switched to placebo at week 21 kept 61% of their loss (press release).
Trial
Side effects and what to do
Nausea (43% vs 20% on placebo over 13 weeks)
Mostly mild, none severe, and mostly early. Smaller meals help; ongoing vomiting needs medical advice.
Vomiting (18% vs 0%) and constipation (26% vs 11%)
Fluids and fiber help constipation. Don’t push through repeated vomiting.
Diarrhea (20% vs 9%)
Usually early. Keep up fluids; severe or bloody diarrhea needs medical care.
Faster heart rate (up 3–9 beats a minute vs 1.4 on placebo)
Seen at 13 weeks, as with approved drugs of this class. Report palpitations or a racing heart at rest.
Gallbladder problems (2 of 140 vs 0 on placebo)
Gallstones or gallbladder inflammation. Pain in the upper right belly, fever or yellow skin needs medical care.
Stop and get medical help
Severe belly pain that won’t go away (possible pancreatitis or gallbladder disease), repeated vomiting or signs of dehydration, a lump or swelling in the neck, or face or throat swelling or trouble breathing: get medical help.
Can it cause …?
The side effects people ask about most, answered one by one. Each answer says where it comes from.
- Tiredness
- TrialFatigue: 3–14% by dose vs 3% on placebo over 13 weeks (9% across all doses).
- Headache
- TrialHeadache: 8% across doses vs 11% on placebo over 13 weeks, so no more common than placebo.
- Nausea or vomiting
- TrialNausea 43% vs 20% and vomiting 18% vs 0% on placebo over 13 weeks of injections; with the daily tablet, nausea 58% vs 48% (press release).
- Diarrhea or constipation
- TrialConstipation 26% vs 11% and diarrhea 20% vs 9% on placebo over 13 weeks of weekly injections.
- Dizziness
- TrialDizziness 5% vs 3% and vertigo 3% vs 0% on placebo over 13 weeks; low blood pressure in 4 of 140 vs none.
- Trouble sleeping
- Not reportedTrouble sleeping wasn’t reported in 2 or more people in any dose group of the 13-week trial (140 on VK2735).
- Hair loss
- Not reportedHair loss wasn’t reported in 2 or more people in any dose group of the 13-week trial (140 on VK2735).
- Acne, rash or skin changes
- TrialInjection-site reactions: 11% on VK2735 vs 9% on placebo over 13 weeks.
- Water retention or swelling
- Not reportedFluid retention wasn’t reported in 2 or more people in any dose group of the 13-week trial (140 on VK2735).
- Joint or muscle pain
- TrialJoint pain 4% vs 3% and back pain 3% vs 0% on placebo over 13 weeks.
- Anxiety, low mood or irritability
- Not reportedAnxiety or low mood wasn’t reported in 2 or more people in any dose group of the 13-week trial (140 on VK2735).
- Low or high blood sugar
- TrialIn people without diabetes, fasting glucose fell about 10 mg/dL and HbA1c up to 0.36 points; lows weren’t reported. Effects with insulin or sulfonylureas haven’t been studied.
- Fast heartbeat or blood pressure changes
- TrialHeart rate rose 3–9 beats a minute vs 1.4 on placebo, and systolic blood pressure fell 6.7–11.0 mmHg vs 4.2, over 13 weeks.
- More hunger
- TrialIt curbs appetite: decreased appetite 16% vs 0% on placebo over 13 weeks. People switched to placebo after 21 weeks kept 61% of their loss over the next 12 weeks.
- Liver strain
- Not reportedLiver problems weren’t reported in 2 or more people in any dose group of the 13-week trial (140 on VK2735).
- Kidney problems
- TrialNot a common side effect. One acute kidney injury occurred in the 13-week trial, judged unrelated; one person had drug-related dehydration. Vomiting can dehydrate and strain the kidneys.
- Cancer risk
- PrecautionUnknown: trials have lasted up to 33 weeks. Approved drugs of this class carry a boxed warning for rodent thyroid C-cell tumors; trials exclude people at risk.
Trial: reported in human studies. Precaution: a concern that follows from how it works or from a related drug, not measured. Not reported: studied in people and not reported. A side effect that hasn’t been reported can still happen, especially with long or high-dose use. Any of these across every compound: the side-effect finder.
Who should avoid it
No product label covers VK2735, so these come from human studies and from precautions based on how it works. Most important first.
- Medullary thyroid cancer or MEN 2 history
- PrecautionExcluded from VK2735’s phase 3 trials, personal or family history. Approved drugs of this class, such as tirzepatide, carry a boxed warning for thyroid C-cell tumors seen in rodents.
- History of pancreatitis
- TrialExcluded from the phase 3 trials, so its effect in people who have had pancreatitis is unknown. Approved drugs of this class warn of acute pancreatitis.
- A fast or irregular heartbeat
- TrialHeart rate rose 3–9 beats a minute vs 1.4 on placebo over 13 weeks, and one case of atrial fibrillation was judged possibly related to the drug.
- Diabetic eye disease
- TrialProliferative retinopathy and macular edema are excluded from the phase 3 diabetes trial. Tirzepatide’s label warns that rapid blood-sugar improvement can temporarily worsen diabetic retinopathy.
- People on insulin or sulfonylureas
- PrecautionNot tested with insulin. Tirzepatide’s label warns that adding it to insulin or a sulfonylurea raises the risk of low blood sugar.
- Pregnancy or breastfeeding
- PrecautionNo human safety data exist.
- Anyone relying on product quality
- PrecautionIt isn’t approved anywhere and its structure hasn’t been published, so nothing sold online as VK2735 can be checked for identity, purity or sterility.
Interactions
No interaction studies have been published, and no product label lists any. Tirzepatide’s label warns that slower stomach emptying can weaken birth-control pills after starting or raising the dose; whether VK2735 does the same hasn’t been studied.
Trial: seen in human studies, or a group those studies left out. Precaution: follows from how it works or from a related drug, and hasn’t been tested. This isn’t a complete list: a pharmacist or doctor can check a specific medicine or condition. Every documented interaction, by medicine: drug interactions.
Special situations
What’s known about pregnancy, breastfeeding, kidney and liver problems, age and surgery. Where nothing has been studied, the row says so.
- Pregnancy
- PrecautionNo human safety data. Labels of approved drugs of this class, such as Zepbound, say to stop when pregnancy is recognized.
- Breastfeeding
- PrecautionNo human data; it isn’t known whether it passes into breast milk.
- Kidney problems
- PrecautionNo data in kidney disease. Labels of approved drugs of this class warn that vomiting and diarrhea can cause dehydration and acute kidney injury.
- Liver problems
- PrecautionNo data in liver disease; trial results by liver function haven’t been reported.
- Older adults
- PrecautionTrials enrolled adults 18 and over (mean age about 50); results by age haven’t been reported.
- Children and teens
- PrecautionNot approved for any age, and not studied in anyone under 18.
- Surgery and anesthesia
- PrecautionNo data for VK2735. Labels of approved drugs of this class, including tirzepatide, warn that stomach contents can enter the lungs under anesthesia. Tell the surgical team about any injected compound.
Precaution: not studied, so the caution follows from how it works or from a related drug. Ages are given as approved or studied; this site never gives doses for children. Across every compound: pregnancy, breastfeeding, kidney disease, liver disease, older adults and surgery.
Tracking and pairing
Worth tracking
- Heart rate
- Hydration if vomiting or diarrhea is heavy
- Blood sugar if taking diabetes medicines
- Gallbladder symptoms (upper right belly pain)
Often paired with
Usually run on its own.
Human studies
4 key published human studies, with how many people took part. Animal studies aren’t listed here.
-
Weight fell 9.1–14.7% vs 1.7% on placebo, if everyone had stayed on treatment; nausea 43% vs 20%, vomiting 18% vs 0%.
- Design
- Randomized double-blind placebo-controlled dose-finding trial (phase 2), adults with obesity or overweight without diabetes
- Dose
- 2.5, 5, 10 or 15 mg weekly, stepped up every 3 weeks
- Length
- 13 weeks
Bays et al., Obesity 2026 (VENTURE), PMID 41508550
-
Weight fell up to 12.2% vs 1.3% on placebo; 20% stopped for side effects vs 13%.
- Design
- Randomized double-blind placebo-controlled dose-finding trial of a daily tablet (phase 2); results by press release only
- Dose
- 15–120 mg once daily, stepped up every 2 weeks
- Length
- 13 weeks
Viking Therapeutics press release, August 2025 (NCT06828055)
-
Weight fell 16–19% by week 21; less frequent doses kept 82–97% of that loss for 12 weeks vs 61% on placebo.
- Design
- Randomized double-blind placebo-controlled maintenance trial (phase 1); results by press release only
- Dose
- 15–22.5 mg weekly for 21 weeks, then every-other-week, monthly or weekly doses, or placebo
- Length
- 33 weeks
Viking Therapeutics press release, September 2026 (NCT07838740)
-
Weight fell up to 7.8% (6.0% more than placebo) in 28 days; half-life was about 170–250 hours.
- Design
- Randomized double-blind placebo-controlled multiple-dose trial (phase 1); results by press release only
- Dose
- 0.5–10 mg weekly, some cohorts stepped up
- Length
- 4 weeks
Viking Therapeutics press release, March 2023 (NCT05203237)
Trials under way
Registered trials that are still running, or that finished without published results, most important first. Checked on ClinicalTrials.gov, October 7, 2026.
VANQUISH 1: weekly VK2735 7.5, 12.5 or 17.5 mg vs placebo for 78 weeks in about 4,500 adults with obesity or overweight without diabetes: weight change
Active, not recruiting; main results expected July 2027
VANQUISH 2: the same doses vs placebo for 78 weeks in about 1,000 adults with type 2 diabetes and overweight: weight change
Active, not recruiting; main results expected July 2027
Maintenance study: 21 weeks of weekly injections, then every-other-week, monthly or oral doses vs placebo in adults with obesity: safety and weight
Recruiting for part 2 (oral maintenance, from October 2026); part 1 results by press release; completion expected 2027
VENTURE-Oral Dosing: daily tablet 15–120 mg vs placebo for 13 weeks in 280 adults with obesity: weight change
Completed August 2025; results by press release only
Every compound’s registered trials: trials under way.
Limits of the evidence
VK2735 has one published trial: 13 weeks of weekly injections in 176 adults (VENTURE). A 13-week tablet trial in 280 adults and a 33-week maintenance study in about 180 are known only from company press releases, and phase 1 data are unpublished. Two 78-week phase 3 trials in about 5,500 people are due to finish in mid-2027. Long-term safety, heart outcomes and anything sold online are untested.
How it’s supplied
Weekly injections of 2.5–15 mg in phase 2 and 7.5–17.5 mg in phase 3; daily tablets of 15–120 mg in a phase 2 trial. Not sold. Injected under the skin once a week, stepped up every 3 weeks in phase 2; tablets were taken once a day, stepped up every 2 weeks. It’s available only in clinical trials, so the calculator and dose log don’t apply.
There’s no product to mix. Trial supplies aren’t sold, and Viking hasn’t published the structure, so powder sold online as VK2735 can’t be checked against the real compound.
Datasheet
- Half-life
- about 7 to 10 days (170 to 250 hours) TrialSingle subcutaneous doses in a phase 1 trial; reported by the company and not yet published in a journal.
- Type
- Peptide
- Molecular weight
- Not published
- Storage before use
- Not published for the trial products; no label exists.
- After mixing or opening
- Not published.
- Half-life: Viking Therapeutics phase 1 results, press release, March 2023 (NCT05203237)
- Molecule: Viking Therapeutics hasn’t published the structure; no FDA GSRS or PubChem compound record (checked October 2026)
- Storage: Community No label, manufacturer or published storage data exist for this compound
Every compound side by side: the half-life chart and the storage chart.
Identifiers
- ATC code
- None assigned
- Development codes
- VK2735 (Viking Therapeutics)
- Brand names
- None; not approved anywhere
- First described
- Developed by Viking Therapeutics; first given to people in a phase 1 trial that began in December 2021.
Every compound’s numbers: the identifiers table.
Product form and quality
No approved product exists, and trial supplies aren’t sold. Viking hasn’t published the structure, so powder sold online as VK2735 can’t be checked for identity, purity or dose against the real compound.
Cautions
- Investigational and not approved anywhere; its phase 3 trials are due to finish in mid-2027.
- Stomach side effects were common: nausea 43% vs 20% and vomiting 18% vs 0% on placebo over 13 weeks of injections.
- With the daily tablet, 20% stopped for side effects vs 13% on placebo (press release).
- Phase 3 trials exclude people with a personal or family history of medullary thyroid cancer or MEN 2, or with past pancreatitis.
- Its structure hasn’t been published, so nothing sold online as VK2735 can be verified.
Questions
What is VK2735?
An investigational weekly injection, also tested as a daily tablet, that activates the GLP-1 and GIP receptors, the same pair tirzepatide targets. It reduces appetite and food intake.
How does VK2735 work?
VK2735 is an experimental peptide that switches on two gut-hormone receptors, GLP-1 and GIP, the same pair tirzepatide targets. GLP-1 signals curb appetite and slow stomach emptying, and both hormones boost insulin release after meals. A side chain lets it last long enough for weekly injections, and a tablet form is also being tested. In trials it lowered weight within 13 weeks. Its structure and how strongly it acts on each receptor haven’t been fully published, and only 13 weeks of data are in a journal. Effects beyond 33 weeks, including on the heart, are unknown.
Is VK2735 FDA-approved?
Not approved in the US or anywhere else. Viking Therapeutics began two phase 3 trials (VANQUISH) in June 2025; both are due to finish in mid-2027. Never nominated for FDA’s 503A or 503B bulk lists and not in any of FDA’s compounding categories (lists updated May 2026 and March 2025). It isn’t part of any approved drug, so it can’t legally be compounded.
What is the usual VK2735 dose?
From human studies (Bays 2026): Weekly injection (phase 2, VENTURE): 2.5, 5, 10 or 15 mg for 13 weeks, stepped up every 3 weeks to the final dose (15 mg: 5, 7.5, 10, then 15 mg). Weight fell 9.1–14.7% vs 1.7% on placebo, if everyone had stayed on treatment. Daily tablet (phase 2): 15–120 mg once a day for 13 weeks, stepped up every 2 weeks. Weight fell up to 12.2% vs 1.3% on placebo, but 20% stopped for side effects vs 13% (Viking press release, Aug 2025). These are the amounts sources reference, not recommendations.
How is VK2735 given?
Injected under the skin once a week, stepped up every 3 weeks in phase 2; tablets were taken once a day, stepped up every 2 weeks. It isn’t sold: it’s available only in clinical trials.
Who should avoid VK2735?
No product label covers VK2735, so these come from human studies and from precautions based on how it works. Medullary thyroid cancer or MEN 2 history: Excluded from VK2735’s phase 3 trials, personal or family history. Approved drugs of this class, such as tirzepatide, carry a boxed warning for thyroid C-cell tumors seen in rodents. History of pancreatitis: Excluded from the phase 3 trials, so its effect in people who have had pancreatitis is unknown. Approved drugs of this class warn of acute pancreatitis. A fast or irregular heartbeat: Heart rate rose 3–9 beats a minute vs 1.4 on placebo over 13 weeks, and one case of atrial fibrillation was judged possibly related to the drug. The “Who should avoid it” section lists 4 more groups.
What is the half-life of VK2735?
About 7 to 10 days (170 to 250 hours), measured in human studies. Single subcutaneous doses in a phase 1 trial; reported by the company and not yet published in a journal.
How should VK2735 be stored?
Before mixing: Not published for the trial products; no label exists. After mixing: Not published. This is common practice; no product label covers it.
Is VK2735 banned in sport?
Probably. Not named on WADA’s 2026 list, but its S0 rule bans drugs with no current human approval anywhere, at all times.
Has VK2735 been studied in people?
Yes. The human studies section lists 4 published studies. The largest, from 2025, included 280 people. Weight fell up to 12.2% vs 1.3% on placebo; 20% stopped for side effects vs 13%.
How long has VK2735 been studied in people?
Trial 33 weeks: about 180 adults in a maintenance study (press release, September 2026). The only published trial ran 13 weeks (140 on VK2735).
Does VK2735 come in other forms, like a pill or nasal spray?
Trial Tested as a weekly injection and as a daily tablet: the tablet gave up to 12.2% loss in 13 weeks, with more people stopping for side effects. No nasal or patch form has been tested.
Can you drink alcohol while taking VK2735?
Precaution No study has looked at alcohol with VK2735. Alcohol can add to nausea and, with diabetes medicines, to low blood sugar; heavy drinking can itself cause pancreatitis.
Can VK2735 be taken with semaglutide or tirzepatide?
Precaution It already acts on the GLP-1 receptor, so adding semaglutide or tirzepatide would double up. No study has combined them; Zepbound’s label advises against tirzepatide with any GLP-1 drug.
What happens if you take too much VK2735?
Precaution No label and no overdose data. Weekly doses up to 22.5 mg have been given in trials; too much would be expected to cause severe nausea, vomiting and dehydration. Call Poison Help (1-800-222-1222), or emergency services for severe symptoms.
Sources
- Bays et al., VENTURE phase 2 trial of weekly VK2735 (Obesity 2026) PMID 41508550
- Viking Therapeutics press release: VENTURE top-line results and dose steps (February 2024)
- Viking Therapeutics press release: VENTURE-Oral Dosing phase 2 results (August 2025)
- Viking Therapeutics press release: maintenance dosing study results (September 2026)
- Viking Therapeutics press release: phase 1 results and half-life (March 2023)
- VANQUISH 1 phase 3 trial record (ClinicalTrials.gov, checked October 2026) NCT07104500
For the protocol details
- Viking Therapeutics press release: VENTURE top-line results, dose steps and weekly nausea rates (February 2024)
- Viking Therapeutics press release: VENTURE-Oral Dosing phase 2 results (August 19, 2025)
- Viking Therapeutics press release: maintenance dosing study results (September 22, 2026)
- VANQUISH 1 and 2 phase 3 trial records (ClinicalTrials.gov) NCT07104383
- Zepbound prescribing information, missed-dose rule (Eli Lilly, rev. 08/2026)
For how it works, who should avoid it and the limits of the evidence
- Zepbound (tirzepatide) prescribing information, boxed warning and sections 5, 7 and 8 (Eli Lilly, rev. 08/2026)
- Viking Therapeutics press releases: oral phase 2 (August 2025) and maintenance study (September 2026)
For uses, the side-effect questions, special situations, trials, identifiers and status outside the US
- Viking Therapeutics first-quarter 2026 results release: VANQUISH enrollment and program plans (April 29, 2026)
- Zepbound (tirzepatide) prescribing information, sections 5 and 8 (Eli Lilly, rev. 08/2026)
- ClinicalTrials.gov records for the VANQUISH trials, NCT07838740, NCT06828055 and the phase 1 trial NCT05203237 (checked October 8, 2026)
- WHO ATC index and Health Canada Drug Product Database searches (October 8, 2026); Australian Poisons Standard, October 2026